<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03076775</url>
  </required_header>
  <id_info>
    <org_study_id>18-1970</org_study_id>
    <secondary_id>1R03HD096188-01</secondary_id>
    <nct_id>NCT03076775</nct_id>
  </id_info>
  <brief_title>Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study</brief_title>
  <acronym>E-ALPS</acronym>
  <official_title>Fetal Metabolic Consequences of Late Preterm Steroid Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Annually in the U.S 300,000 neonates are born late preterm, defined as 34 weeks 0 days - 36
      weeks 6 days. The Antenatal Late Preterm Steroids (ALPS) Trial demonstrated that maternal
      treatment with betamethasone in the late preterm period significantly reduces neonatal
      respiratory complications, but also increases neonatal hypoglycemia, compared to placebo.

      This research study will attempt to answer the following primary question: Does a management
      protocol aimed at maintaining maternal euglycemia after ALPS decrease fetal hyperinsulinemia,
      compared to usual antepartum care?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Euglycemia after Antenatal Late Preterm Steroids, the E-ALPS Study:

      There is a fundamental gap in understanding the adverse metabolic effects of antenatal late
      preterm steroids (ALPS). In 2016, an important randomized clinical trial of 2827 late preterm
      pregnancies showed that antenatal betamethasone (BMZ) significantly reduced neonatal
      respiratory complications compared with placebo. However, those neonates exposed to BMZ were
      also more likely to have hypoglycemia at birth. This unexpected adverse outcome raised
      concern among both obstetricians and neonatologists and remains an important knowledge gap to
      be filled. The rationale for the proposed research is that steroid-induced maternal
      hyperglycemia leads to transient fetal hyperinsulinemia, which causes hypoglycemia in
      neonates that are delivered during this time-period. Thus, the fetal metabolic consequences
      and subsequent neonatal hypoglycemia observed after exposure to BMZ in utero can be prevented
      by achieving maternal euglycemia prior to delivery.

      This protocol describes a randomized clinical trial to evaluate whether screening for and
      treatment of steroid-induced hyperglycemia in non-diabetic women treated with BMZ in the late
      preterm period can decrease the rate of fetal hyperinsulinemia, thus reducing neonatal
      hypoglycemia and improving short-term neonatal outcomes.

      This study was formerly approved as Institutional Review Board #16-3200.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2017</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Umbilical cord blood C-peptide</measure>
    <time_frame>Delivery</time_frame>
    <description>C-peptide level (mcg/L) as measure of fetal hyperinsulinemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neonatal hypoglycemia</measure>
    <time_frame>48 hours of life</time_frame>
    <description>Neonatal capillary blood glucose &lt; 40 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal intensive care unit admission</measure>
    <time_frame>Date of delivery to date of discharge from hospital, assessed up to 28 days</time_frame>
    <description>Admission to the neonatal intensive care unit for &gt; 24 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Pregnancy Preterm</condition>
  <condition>Neonatal Hypoglycemia</condition>
  <condition>Hyperglycemia Drug Induced</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women will undergo regular maternal blood glucose screening and treatment of hyperglycemia following BMZ administration to achieve maternal glycemic control until delivery or hospital discharge, for a maximum of 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine antenatal care will be performed without any maternal blood glucose screening nor treatment as is usual care at each of the study sites.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Maternal glycemic control</intervention_name>
    <description>Maternal capillary blood glucose testing will be performed according to oral intake status: every 2 hours if not eating (NPO) or fasting and 1-hour postprandial if eating regular meals. Hyperglycemia, defined based on the American Diabetes Association and the American College of Obstetricians and Gynecologists recommendations as well as current practice at study sites, will be treated according to study guidelines based on oral intake status: insulin infusion if NPO and subcutaneous insulin if eating regular meals.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Singleton gestation with no known major fetal anomalies

          2. Gestational age at randomization between 34 weeks 0 days and 36 weeks 5 days

          3. Receiving antenatal betamethasone due to high probability of delivery in late preterm
             period

        Exclusion Criteria:

          1. Pre-gestational or gestational diabetes mellitus

          2. Maternal contraindication to insulin

          3. Planned outpatient treatment with antenatal betamethasone

          4. Participation in clinical trial that could affect primary outcome or participation in
             this trial in a previous pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Recruiting pregnant females</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley N Battarbee, MD, MSCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Boggess, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley N Battarbee, MD, MSCR</last_name>
    <phone>2059752361</phone>
    <email>anbattarbee@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kim Boggess, MD</last_name>
    <email>kim_boggess@med.unc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley N Battarbee, MD, MSCR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim A Boggess, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gyamfi-Bannerman C, Thom EA, Blackwell SC, Tita AT, Reddy UM, Saade GR, Rouse DJ, McKenna DS, Clark EA, Thorp JM Jr, Chien EK, Peaceman AM, Gibbs RS, Swamy GK, Norton ME, Casey BM, Caritis SN, Tolosa JE, Sorokin Y, VanDorsten JP, Jain L; NICHD Maternalâ€“Fetal Medicine Units Network. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J Med. 2016 Apr 7;374(14):1311-20. doi: 10.1056/NEJMoa1516783. Epub 2016 Feb 4.</citation>
    <PMID>26842679</PMID>
  </reference>
  <reference>
    <citation>Martin JA, Hamilton BE, Osterman MJ, Driscoll AK, Mathews TJ. Births: Final Data for 2015. Natl Vital Stat Rep. 2017 Jan;66(1):1.</citation>
    <PMID>28135188</PMID>
  </reference>
  <reference>
    <citation>McIntire DD, Leveno KJ. Neonatal mortality and morbidity rates in late preterm births compared with births at term. Obstet Gynecol. 2008 Jan;111(1):35-41. doi: 10.1097/01.AOG.0000297311.33046.73.</citation>
    <PMID>18165390</PMID>
  </reference>
  <reference>
    <citation>Consortium on Safe Labor, Hibbard JU, Wilkins I, Sun L, Gregory K, Haberman S, Hoffman M, Kominiarek MA, Reddy U, Bailit J, Branch DW, Burkman R, Gonzalez Quintero VH, Hatjis CG, Landy H, Ramirez M, VanVeldhuisen P, Troendle J, Zhang J. Respiratory morbidity in late preterm births. JAMA. 2010 Jul 28;304(4):419-25. doi: 10.1001/jama.2010.1015.</citation>
    <PMID>20664042</PMID>
  </reference>
  <reference>
    <citation>Gilbert WM, Nesbitt TS, Danielsen B. The cost of prematurity: quantification by gestational age and birth weight. Obstet Gynecol. 2003 Sep;102(3):488-92.</citation>
    <PMID>12962929</PMID>
  </reference>
  <reference>
    <citation>Jolley JA, Rajan PV, Petersen R, Fong A, Wing DA. Effect of antenatal betamethasone on blood glucose levels in women with and without diabetes. Diabetes Res Clin Pract. 2016 Aug;118:98-104. doi: 10.1016/j.diabres.2016.06.005. Epub 2016 Jun 17.</citation>
    <PMID>27351800</PMID>
  </reference>
  <reference>
    <citation>Langen ES, Kuperstock JL, Sung JF, Taslimi M, Byrne J, El-Sayed YY. Maternal glucose response to betamethasone administration. Am J Perinatol. 2015 Feb;30(2):143-8. doi: 10.1055/s-0034-1376387. Epub 2014 Jun 10.</citation>
    <PMID>24915559</PMID>
  </reference>
  <reference>
    <citation>Shelton SD, Boggess KA, Smith T, Herbert WN. Effect of betamethasone on maternal glucose. J Matern Fetal Neonatal Med. 2002 Sep;12(3):191-5.</citation>
    <PMID>12530617</PMID>
  </reference>
  <reference>
    <citation>Refuerzo JS, Garg A, Rech B, Ramin SM, Vidaeff A, Blackwell SC. Continuous glucose monitoring in diabetic women following antenatal corticosteroid therapy: a pilot study. Am J Perinatol. 2012 May;29(5):335-8. doi: 10.1055/s-0031-1295642. Epub 2011 Nov 17.</citation>
    <PMID>22094918</PMID>
  </reference>
  <reference>
    <citation>Sifianou P, Thanou V, Karga H. Metabolic and hormonal effects of antenatal betamethasone after 35 weeks of gestation. J Pediatr Pharmacol Ther. 2015 Mar-Apr;20(2):138-43. doi: 10.5863/1551-6776-20.2.138.</citation>
    <PMID>25964731</PMID>
  </reference>
  <reference>
    <citation>Obenshain SS, Adam PA, King KC, Teramo K, Raivio KO, RÃ¤ihÃ¤ N, Schwartz R. Human fetal insulin response to sustained maternal hyperglycemia. N Engl J Med. 1970 Sep 10;283(11):566-70.</citation>
    <PMID>5450610</PMID>
  </reference>
  <reference>
    <citation>KÃ¼hl C, Andersen GE, Hertel J, MÃ¸lsted-Pedersen L. Metabolic events in infants of diabetic mothers during first 24 hours after birth. I. Changes in plasma glucose, insulin and glucagon. Acta Paediatr Scand. 1982 Jan;71(1):19-25.</citation>
    <PMID>6753468</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologistsâ€™ Committee on Obstetric Practice; Society for Maternalâ€“ Fetal Medicine. Committee Opinion No.677: Antenatal Corticosteroid Therapy for Fetal Maturation. Obstet Gynecol. 2016 Oct;128(4):e187-94. doi: 10.1097/AOG.0000000000001715.</citation>
    <PMID>27661658</PMID>
  </reference>
  <reference>
    <citation>Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery. Am J Obstet Gynecol. 2016 Aug;215(2):B13-5. doi: 10.1016/j.ajog.2016.03.013. Epub 2016 Mar 15. Review. Erratum in: Am J Obstet Gynecol. 2017 Feb;216(2):180.</citation>
    <PMID>26992737</PMID>
  </reference>
  <reference>
    <citation>ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational diabetes mellitus. Obstet Gynecol. 2005 Mar;105(3):675-85.</citation>
    <PMID>15738045</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. Standards of medical care in diabetes - 2016. Diabetes Care. 2016; 39(suppl1):S1-S106.</citation>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2017</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Betamethasone</keyword>
  <keyword>Late preterm</keyword>
  <keyword>Steroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data collected as a part of this trial will only be available to the study team. Protected health information will only be available to the recruiting site in order to complete data abstraction.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

